Medivation Shares Surge, after Recent New Drug Announcement
Submitted by Neeraj Shahane on Thu, 02/02/2012 - 13:08
It has been recently revealed that there has been the development of the most effective drug so far, treating prostate cancer. There has been a rise in the shares of the Medivation firm, ever since they have made this announcement. They have risen by 22%. It happens to be the largest increase in a day. Also, it is the double of what they had incurred on the 3rd of November last year.
Kalydeco Drug Gets Approval from FDA
Submitted by Neeraj Shahane on Wed, 02/01/2012 - 12:55
It has been reported that drug called Kalydeco has been approved by the US Food and Drug Administration (FDA) for treating cystic fibrosis. The pill thus approved would target the genetic mutation which causes the disease.
FDA Approves Pfizer’s New Drug for Advanced RCC
Submitted by Dinesh Chandra Gaur on Mon, 01/30/2012 - 12:34
It has been uncovered in a recent report that Pfizer, a research-based pharmaceutical company, has got the approval of the FDA (Food and Drug Administration) for a new drug INLYTA (axitinib). The report says that the drug is highly beneficial for the patients with advanced RCC or Renal Cell Carcinoma.
FDA Approves Bydureon For Type 2 Diabetic Patients
Submitted by Pallavi Sharma on Sat, 01/28/2012 - 11:33
It has been informed that a drug potential of treating Type 2 diabetes has got approval by the federal court on Friday. The drug manufacturers have been seeking approval from past many years.
Baby Lotion of Johnson & Johnson Recalled
Submitted by Neeraj Shahane on Sat, 01/28/2012 - 11:30
On Fridays, the Johnson & Johnson recalled its Aveeno Baby Calming Comfort Lotion from the market. The recall was called after the products failed to meet the standards set by Food and Drug Administration (FDA).
FDA Approves “Tysabri” for Multiple Sclerosis
Submitted by Dinesh Chandra Gaur on Sat, 01/21/2012 - 13:19
A report has revealed that the Food and Drug Administration has given green signal to Biogen Idec Inc. and Elan Corp. for their multiple sclerosis drug Tysabri which would now be available in the US market.
